+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Anti-Obesity Drugs Market (2021-2026) by Drug Type, Drug Class, Medication, Distribution Channel, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • ID: 5397312
  • Report
  • May 2021
  • Region: Global
  • 186 pages
  • Infogence Global Research
UP TO OFF
until Nov 30th 2021
The Global Anti-Obesity Drugs Market is Estimated to Be USD 3.28 Bn in 2021 and is Expected to Reach USD 4.64 Bn by 2026, Growing at a CAGR of 7.19%

FEATURED COMPANIES

  • Alizyme
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche AG
  • Norgine BV,
  • Pfizer Inc
  • Shionogi Inc
The Global Anti-Obesity Drugs Market is estimated to be USD 3. 28 Bn in 2021 and is expected to reach USD 4.64 Bn by 2026, growing at a CAGR of 7.19%.



Market Dynamics
Increased consumption of processed and unhealthy foods, lack of physical activity, lack of knowledge about the risk associated with obesity, and rising disposable money are some factors driving the demand for anti-obesity drugs. Furthermost, the rising worry about being overweight or obese is exposing people to a greater risk of developing a variety of chronic illnesses, such as cardiovascular disease, cancer, and diabetes, etc., all of which have high treatment costs, so the public has become more conscious of obesity, which is prompting consumers to turn to anti-obesity medications. In addition, the increasing healthcare spending, favorable reimbursement policies, substantial research and development efforts in the sector, and increased government and non-government organizations' participation in raising awareness and funding research are expected to create more opportunities for the growth of this market.

However, medication side effects, restricted availability of combination therapy, and growing acceptance of other options such as gyms, exercise spas, and other alternatives are likely to restrain and create a challenge for the global anti-obesity drugs market.

Market Segmentation

The Global Anti-Obesity Drugs Market is segmented further based on Drug Type, Drug Class, Medication, Distribution Channel, and Geography.

By Drug Type, the market is classified as prescription drugs and OTC drugs. Amongst the two, the prescription drugs segment is estimated to hold the highest market share during the forecast period.

By Drug Class, the market is classified as peripherally acting drugs and centrally acting drugs. Amongst the two, the peripherally acting drugs segment is estimated to hold the highest market share during the forecast period.

By Medication, the market is classified as Monotherapies, Polytherapies, and others, others. Amongst all, the monotherapies segment is estimated to hold the highest market share during the forecast period.

By Distribution Channel, the market is classified as hospital pharmacy, retail pharmacy, and online pharmacy. All the hospital pharmacy segment is estimated to hold the highest market share during the forecast period.

By Geography, North America is projected to lead the market.

Recent Developments

1. FDA accepts Eisai's supplemental new drug application (SNDA) to update the labeling for anti-obesity agent Belviq. - 25th February 2019.
2. Currax™ Pharmaceuticals LLC Announces the Acquisition of Nalpropion Pharmaceuticals, Inc. - 27th September 2019.
3. Currax Launches Why Weight: Communicate Initiative to Encourage Conversations about Weight Loss- 25th June 2021

Company Profiles

Some of the companies covered in this report are Alizyme, Arena Pharmaceuticals Inc, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Currax Pharmaceuticals LLC, etc.

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?
  • The report offers a comprehensive evaluation of the Global Anti-Obesity Drugs Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst's Proprietary competitive positioning tool.
Report Highlights:
  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alizyme
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche AG
  • Norgine BV,
  • Pfizer Inc
  • Shionogi Inc
1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Shareholders

2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study

3 Executive Summary
3.1 Introduction
3.2 Market Size and Segmentation
3.3 Market Outlook

4 Market Influencers
4.1 Drivers
4.1.1 Increasing Consumption of Unhealthy food
4.1.2 Adoption of Unhealthy lifestyle
4.2 Restraints
4.2.1 Side Effect of Anti-Obesity Drug
4.3 Opportunities
4.3.1 Raising Public Awareness Towards a Healthy Lifestyle
4.4 Challenges
4.4.1 Alternate Treatment Options Available
4.4.2 Lack of Proper Awareness towards Weight Management
4.5 Trends

5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis

6 Global Anti-Obesity Drugs Market, By Drug Type
6.1 Introduction
6.2 Prescription Drugs
6.3 OTC Drugs

7 Global Anti-Obesity Drugs Market, By Drug Class
7.1 Introduction
7.2 Peripherally Acting Drugs
7.3 Centrally Acting Drugs

8 Global Anti-Obesity Drugs Market, By Medication
8.1 Introduction
8.2 Monotherapies
8.3 Polytherapies
8.4 Others

9 Global Anti-Obesity Drugs Market, By Distribution Channel
9.1 Introduction
9.2 Hospital Pharmacy
9.3 Retail Pharmacy
9.4 Online Pharmacy

10 Global Anti-Obesity Drugs Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 South America
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Chile
10.3.4 Colombia
10.4 Europe
10.4.1 UK
10.4.2 France
10.4.3 Germany
10.4.4 Italy
10.4.5 Spain
10.4.6 Netherlands
10.4.7 Sweden
10.4.8 Russia
10.4.9 Rest of Europe
10.5 Asia-Pacific
10.5.1 China
10.5.2 Japan
10.5.3 India
10.5.4 Indonesia
10.5.5 Malaysia
10.5.6 South Korea
10.5.7 Australia
10.5.8 Sri Lanka
10.5.9 Thailand
10.5.10 Rest of APAC
10.6 Middle-East and Africa
10.6.1 Qatar
10.6.2 Saudi Arabia
10.6.3 South Africa
10.6.4 United Arab Emirates

11 Competitive Landscape
11.1 Competitive Quadrant
11.2 Market Share Analysis
11.3 Strategic Initiatives
11.3.1 M&A and Investments
11.3.2 Partnerships and Collaborations
11.3.3 Product Developments and Improvements

12 Company Profiles
12.1 Alizyme
12.2 Arena Pharmaceuticals Inc
12.3 Bayer AG
12.4 Boehringer Ingelheim GmbH
12.5 Bristol-Myers Squibb
12.6 Currax Pharmaceuticals LLC
12.7 Eisai Co. Ltd
12.8 F. Hoffmann-La Roche AG
12.9 GlaxoSmithKline PLC
12.10 Merck & Co. Inc
12.11 Norgine BV,
12.12 Novo Nordisk A
12.13 Orexigen Therapeutics
12.14 Pfizer Inc
12.15 Rhythm Pharmaceuticals
12.16 Shionogi Inc
12.17 Sanofi
12.18 Takeda Pharmaceuticals
12.19 Vivus Inc
12.20 Zydus Cadila

13 Appendix
13.1 Questionnaire
Note: Product cover images may vary from those shown
  • Alizyme
  • Arena Pharmaceuticals Inc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Currax Pharmaceuticals LLC
  • Eisai Co. Ltd
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co. Inc
  • Norgine BV,
  • Novo Nordisk A
  • Orexigen Therapeutics
  • Pfizer Inc
  • Rhythm Pharmaceuticals
  • Shionogi Inc
  • Sanofi
  • Takeda Pharmaceuticals
  • Vivus Inc
  • Zydus Cadila
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll